Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.33

Mkt cap

5.4M

Volume

23K

High

1.34

P/E Ratio

-1.07

52-wk high

6.80

Low

1.32

Div yield

N/A

52-wk low

0.92

Clearmind Medicine shares rose following the announcement of a patent approval from the US Patent and Trademark Office.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:15 pm

Clearmind Medicine has received a new patent approval from the US Patent and Trademark Office for its MEAI-based binge behavior regulator program. This marks a significant advancement in their proprietary program.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:12 pm

Clearmind Medicine shares are trading higher following the announcement of an international patent submission in collaboration with the Yissum Research Development Company.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 8:22 pm

Clearmind Medicine Inc. (NASDAQ:CMND) has submitted an international patent application for generation 3.0 psychedelic compounds to treat mental disorders, in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 8:15 pm

Doximity, Inc. (NYSE:DOCS) shares surged over 28% in pre-market trading after reporting better-than-expected Q1 financial results and issuing strong FY24 revenue guidance. Other notable pre-market movers include Iteris, Inc. (NASDAQ:ITI) up 61.7% due to an acquisition, and American Vanguard Corporation (NYSE:AVD) down 30.8% after disappointing Q2 results.

Portfolio Pulse from Avi Kapoor

August 09, 2024 | 9:04 am

SciSparc Ltd. (NASDAQ: SPRC) and Clearmind Medicine Inc. (NASDAQ: CMND) have published a new scientific article showing promising results for MEAI, a novel weight loss drug. The study, led by Prof. Joseph Tam, indicates potential for MEAI in treating obesity and metabolic syndrome.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:14 pm

Clearmind Medicine has entered into a partnership to source global manufacturers and distributors for its MEAI-based alcohol substitute beverages, marking a significant step towards international expansion.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:01 pm

U.S. stocks traded mostly higher with the Dow Jones surging over 650 points. Morgan Stanley reported better-than-expected Q2 results. Silo Pharma, Yoshitsu Co., and AngioDynamics saw significant stock price increases, while Reddit, Charles Schwab, and Clearmind Medicine experienced declines.

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 6:31 pm

Shares of The Charles Schwab Corporation (NYSE:SCHW) fell over 7% following their second-quarter results, which showed a decline in adjusted net income and EPS. Other stocks such as Yoshitsu Co., Ltd (NASDAQ:TKLF) and Silo Pharma, Inc. (NASDAQ:SILO) saw significant gains, while Cyngn Inc. (NASDAQ:CYN) and Autonomix Medical, Inc. (NASDAQ:AMIX) experienced notable declines.

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 5:06 pm

U.S. stocks saw significant gains with the Dow Jones rising over 400 points. Retail sales for June were flat, and industrials led the market with a 1.2% increase. Notable stock movements included Silo Pharma, Yoshitsu Co., and Logistic Properties of the Americas, which saw substantial gains, while Autonomix Medical, Cyngn Inc., and Clearmind Medicine experienced declines.

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 2:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.